PQM130
规格
| Cas Number | 2089415-51-8 |
| 规格或纯度 | ≥99% |
| 纯度 | ≥99% |
| 包装 | 100mg 或 50mg 或 10mg 或 5mg 或 25mg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | DMSO : 1.82 mg/mL (4.77 mM; ultrasonic and warming and heat to 60°C) |
| 过滤标签 | Amyloid-β,神经元信号传导 |
| 储存温度 | 避光,-80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | PQM130 是一种阿魏酰-多奈哌齐混合化合物，具有脑穿透性，是一种抗 Aβ 1-42 寡聚体（AβO）诱导的神经毒性的多靶点候选药物，并具有抗炎活性。PQM130 可作为一种神经保护化合物，用于抗 Aβ 1-42 低聚物（AβO）诱导的神经毒性。 |
| 英文描述 |
PQM130, a Feruloyl-Donepezil Hybrid compound with brain penatration, is a multitarget agent candidate against the neurotoxicity induced by Aβ 1-42 oligomer (AβO) and shows anti-inflammatory activity. PQM130 acts as a neuroprotective compound for anti-AD agent development. In Vivo PQM130 (0.5-1 mg/kg, i.p., daily for 10 days) treatment after the i.c.v. AβO injection reduces oxidative damage and neuroinflammation and induces cell survival and protein synthesis through the modulation of GSK3β and extracellular signal-regulated kinases (ERK1/2) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Adult male C57Bl/6 mice (9 weeks old, 25-30 g body weight) . Dosage: 0.5 and 1.0 mg/kg. Administration: IP injection daily for 10 days. Result: Ameliorated Aβ 1-42 O-induced cognitive deficits in mice. Prevented Aβ 1-42 O-induced neuronal death in mice. Antagonized Aβ 1-42 O-Induced Oxidative Stress in Mice. Regulated GSK3β and ERK1/2 protein expressions in mice. Reduced Aβ 1-42 O-induced astrocytic activation in mice. Form:Solid |